Pharma Focus Asia
MasterControl - Avoid Falling Behind the Pharma Market

Talaris Therapeutics Develops Novel Cell Therapy FCR001 for the Treatment of Scleroderma

Novel cell therapy FCR001, was developed by Talaris for the treatment of patients with diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma.

Scleroderma, a rare and potentially fatal chronic autoimmune disease causes progressive scarring, or fibrosis, in the body’s connective tissues. Systemic scleroderma, also called systemic sclerosis (SSc) affects the skin and vital internal organs, especially the lungs, kidneys, gut and heart, resulting in organ dysfunction.

It is believed that FCR001 serve as a new treatment option for patients suffering with diffuse cutaneous systemic sclerosis, a subset of scleroderma with high morbidity and mortality. In addition, for individuals who need great need of safe and effective, disease-modifying, treatment, FCR001 would be the better option.

FCR001 is an investigational, allogeneic cell therapy developedto induce or restore patients’ immune tolerance.

Investigational New Drug (IND) FCR001has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Increasing the likelihood of your drug approvalMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® productsMedical Fair Thailand 20235th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023
MasterControl - 6 Essential Features in an eQMS